The absolute event rates for serious infections were low (2 to 4 events per 100 person‐years of follow‐up) in the JAK1 trials and are comparable to those of TNF inhibitors (TNFi) – with the exception of reactivations of latent viruses such as VZV, HSV and cytomegalovirus.14 Here, TNF is linked to infection.